ModalisX

Every Life Deserves Attention

Tokyo, Japan · Founded 2016

Headquarters
Tokyo
Employees
11–50
Founded
2016
Business Model
B2B

About

Modalis Therapeutics (ModalisX) is a Tokyo-based clinical-stage biotech company pioneering epigenome editing as a treatment platform for genetic diseases. Founded in 2016 by Haru Morita and Osamu Nureki, the company developed CRISPR-GNDM®, a proprietary technology that selectively activates or suppresses specific genes without altering the DNA sequence, enabling therapies delivered via AAV vectors. Modalis is listed on the Tokyo Stock Exchange Mothers market (ticker 4883) and has active collaborative pipelines in muscular disorders, cardiomyopathy, CNS disorders, and FSHD.

Summary

ModalisX is a Biotech company based in Tokyo, Japan, founded in 2016.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Similar Companies

ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ModalisX on Indexed.vc
<a href="https://indexed.vc/companies/modalisx"><img src="https://indexed.vc/api/badge/company/modalisx" alt="ModalisX on Indexed.vc" width="260" height="76" /></a>